The patients received Lutetium (177Lu) rhPSMA-10.1 Injections at both St Bartholomew's Hospital, London, and The James Cook University Hospital, Middlesbrough -- Lutetium (177Lu) rhPSMA-10.1 Injection ...
Sintilimab, marketed as TYVYT® (sintilimab injection) in China, is a PD-1 immunoglobulin G4 monoclonal antibody co-developed by Innovent and Eli Lilly and Company. Sintilimab is a type of ...
Injections and infusions are a common way to receive chemotherapy. Both methods deliver cancer-treating medications directly into the bloodstream. Chemotherapy is a common cancer treatment that uses ...
Nanobiotix (NASDAQ:NBTX) traded higher on Thursday after the French biotech announced initial results from a Phase 1 trial for JNJ-1900 (NBTXR3), a cancer injection developed by the company in ...
SAN FRANCISCO, U.S. and SUZHOU, China, Dec. 3, 2024 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and ...
— First regulatory approval for fruquintinib combination therapy with an immune checkpoint inhibitor — “This approval of fruquintinib plus sintilimab could represent a paradigm shift in managing this ...
The FDA approved Merck's proposed method of administering its Keytruda cancer drug by injection rather than intravenous. Merck said Friday the injection, called Keytruda Qlex, has shown comparable ...
Experimental mRNA cancer vaccine shows potential for advanced stage cancer patients in Phase 1 trial
Interim data from the Phase I dose escalation part of the mRNA cancer immunotherapy (mRNA-4359), show promise in patients with advanced solid cancers. The investigational mRNA cancer immunotherapy is ...
Based on the results from the Phase 3 PALOMA-3 study, Rybrevant Faspro delivered consistent results to Rybrevant, meeting both co-primary pharmacokinetic (PK) endpoints. Data presented at ASCO in 2024 ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback